Navigation Links
Angiotech announces director resignation
Date:4/15/2008

VANCOUVER, April 15 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, announced the resignation of Greg Peet from his position as a non-executive director of the Company. Mr. Peet has resigned to enable him to focus on his numerous business pursuits and additional board appointments. Mr. Peet has served on Angiotech's Board of Directors since 2005. This position will not be replaced at the current time and the remaining six directors will continue to carry out the duties of the board.

"The board and management would like to thank Greg for his many contributions to the Company's development," said David Howard, Angiotech's Chairman of the Board. "We wish him well in his future endeavours."

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Deirdre Neary, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
2. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
3. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
4. Angiotech to participate in Lehman Brothers Healthcare Conference
5. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
6. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
7. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
8. Angiotech announces results for the fourth quarter ended December 31, 2007
9. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
11. Angiotech and Symphony Medical Announce Licensing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon ... awards honoring scientists who have made outstanding contributions to analytical chemistry ... Pittcon 2018, the world’s leading conference and exposition for laboratory science, which will ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):